10.38
price up icon2.27%   0.23
pre-market  Pre-market:  10.50   0.12   +1.16%
loading
Rapport Therapeutics Inc stock is traded at $10.38, with a volume of 118.75K. It is up +2.27% in the last 24 hours and up +6.79% over the past month. Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$10.15
Open:
$9.98
24h Volume:
118.75K
Relative Volume:
0.60
Market Cap:
$359.12M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.49%
1M Performance:
+6.79%
6M Performance:
-58.01%
1Y Performance:
+0.00%
1-Day Range:
Value
$9.81
$10.64
1-Week Range:
Value
$9.01
$10.64
52-Week Range:
Value
$7.13
$29.74

Rapport Therapeutics Inc Stock (RAPP) Company Profile

Name
Name
Rapport Therapeutics Inc
Name
Phone
857-321-8020
Name
Address
1325 BOYLSTON STREET, BOSTON
Name
Employee
69
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
RAPP's Discussions on Twitter

Compare RAPP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RAPP
Rapport Therapeutics Inc
10.38 359.12M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-08-25 Initiated Citizens JMP Mkt Outperform
Jul-02-24 Initiated Jefferies Buy
Jul-02-24 Initiated Stifel Buy
Jul-02-24 Initiated TD Cowen Buy

Rapport Therapeutics Inc Stock (RAPP) Latest News

pulisher
12:12 PM

When the Price of (RAPP) Talks, People Listen - news.stocktradersdaily.com

12:12 PM
pulisher
Apr 17, 2025

Rapport therapeutics chief scientific officer sells $81,310 of stock - Investing.com Australia

Apr 17, 2025
pulisher
Apr 16, 2025

Rapport therapeutics chief scientific officer sells $81,310 of stock By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 13, 2025

KLP Kapitalforvaltning AS Purchases Shares of 1,900 Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges Bank - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Comparing Rapport Therapeutics (RAPP) & The Competition - Defense World

Apr 12, 2025
pulisher
Apr 10, 2025

Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at JMP Securities - Defense World

Apr 10, 2025
pulisher
Apr 08, 2025

JMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform Recommendation - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

Citizens JMP sets $28 target for Rapport Therapeutics stock By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 05, 2025

(RAPP) Investment Analysis - news.stocktradersdaily.com

Apr 05, 2025
pulisher
Apr 02, 2025

nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

Apr 02, 2025
pulisher
Mar 31, 2025

Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 31, 2025

Swiss National Bank Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Mar 31, 2025
pulisher
Mar 27, 2025

Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

(RAPP) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 26, 2025
pulisher
Mar 26, 2025

Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 26, 2025
pulisher
Mar 23, 2025

Vanda Pharmaceuticals (NASDAQ:VNDA) and Rapport Therapeutics (NASDAQ:RAPP) Financial Contrast - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Rapport Therapeutics to present data at 2025 AAN meeting - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire

Mar 21, 2025
pulisher
Mar 21, 2025

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire Inc.

Mar 21, 2025
pulisher
Mar 15, 2025

Several Insiders Invested In Rapport Therapeutics Flagging Positive News - simplywall.st

Mar 15, 2025
pulisher
Mar 15, 2025

Positive Signs As Multiple Insiders Buy Rapport Therapeutics Stock - Yahoo

Mar 15, 2025
pulisher
Mar 15, 2025

Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares - Yahoo Finance

Mar 15, 2025
pulisher
Mar 14, 2025

Rapport Therapeutics director Wendy Young acquires $61,249 in stock By Investing.com - Investing.com India

Mar 14, 2025
pulisher
Mar 13, 2025

Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock By Investing.com - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Rapport Therapeutics Executives Acquire Shares - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Rapport Therapeutics director Wendy Young acquires $61,249 in stock - Investing.com

Mar 13, 2025
pulisher
Mar 11, 2025

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Rapport Therapeutics Reports Q4 Net Loss Of $19.98 Mln - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Rapport Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Rapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last year - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Rapport Therapeutics Inc Q4 Net Loss $20.0 Million -March 11, 2025 at 07:20 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Has $182,000 Stock Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

New York State Common Retirement Fund Acquires New Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

(RAPP) On The My Stocks Page - Stock Traders Daily

Mar 05, 2025
pulisher
Mar 04, 2025

Head of R&D Robert Lenz to leave Neumora - BioCentury

Mar 04, 2025
pulisher
Mar 03, 2025

Rapport Therapeutics appoints new chief medical officer By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 03, 2025

Rapport Therapeutics, Inc. Announces Appointment of Jeffrey Sevigny as Chief Medical Officer - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Rapport Therapeutics appoints new chief medical officer - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Rapport Therapeutics Announces Appointment of Dr. Jeffrey - GlobeNewswire

Mar 03, 2025
pulisher
Feb 24, 2025

Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Feb 24, 2025
pulisher
Feb 22, 2025

Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5%Here's What Happened - MarketBeat

Feb 20, 2025
pulisher
Feb 13, 2025

Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat

Feb 13, 2025
pulisher
Feb 12, 2025

How To Trade (RAPP) - Stock Traders Daily

Feb 12, 2025
pulisher
Feb 11, 2025

Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.6%What's Next? - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

Jennison Associates LLC Acquires Shares of 62,287 Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat

Feb 10, 2025

Rapport Therapeutics Inc Stock (RAPP) Financials Data

There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Rapport Therapeutics Inc Stock (RAPP) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Bredt David
Chief Scientific Officer
Mar 14 '25
Sale
10.85
8,500
92,205
469,142
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Cap:     |  Volume (24h):